Pyoderma gangrenosum (PG) occurs in approximately 1 in 100,000 people each year.1 PG primarily occurs between ages of 40 and 60 years. PG is often coincident in patients with systemic inflammatory disease (eg, arthritis, inflammatory bowel disease, and hematologic malignancies). PG is not a manifestation or complication of these diseases, rather it is a separate entity. The severity and duration of PG are not related to activity of the comorbid diseases.2
PG is considered a reactive neutrophilic dermatosis. It is believed that PG is caused by lymphocytic antigen activation resulting in cytokine release and neutrophil recruitment. This results in marked soft-tissue necrosis.2
Lesions of PG are classified morphologically into 4 types: ulcerative (most common), bullous, pustular, and vegetative. Lesions can appear on normal skin or at sites of trauma (eg, pathergy). Pathergy complicates wound healing and surgical interventions by forming satellite lesions at skin manipulation sites. PG’s hallmark violaceous lesions are progressive and may demonstrate central ulceration.2 Histologically, lesions show neutrophilic infiltration, with abscess formation in the mid to deep dermis.2 Tissue at the ulcer edge predominantly shows lymphocytic infiltrate. Lymphocytes may be seen infiltrating blood vessel walls with intramural or intravascular fibrin deposition.3
We present a case of PG following abdominal wall reconstruction. This case details the diagnosis and management of PG from what was previously believed to be a surgical site infection.
The patient was a 63-year-old woman with a medical history significant for uterine carcinoma, status-post hysterectomy, and radiation therapy. Her condition was complicated by a 4 cm × 4 cm incisional hernia and radiation enteritis. She underwent a complex abdominal wall reconstruction using component separation technique and underlying porcine mesh. This operation involved extensive lysis of adhesions, cholecystectomy (due to incidental gallstones), and prophylactic appendectomy. Abdominal wall flaps were managed with Blake drain placement in each abdominal quadrant.
The patient tolerated the operation well and was transferred to an intermediate care, surgical unit. She had a smooth postoperative course until postoperative day (POD) 6 when erythema without discharge was noted around the incision. She was started on IV antibiotics, and appropriate sepsis workup was obtained. CT scanning demonstrated no significant fluid collections within the flap space or intra-abdominally.
On POD 7, purulent drainage appeared from the incision. She was taken to the operating room for exploration of the abdominal flaps with pulse irrigation, lavage, and placement of a negative pressure dressing. Intraoperative findings revealed necrotic dermis, viable adipose tissue, and intact abdominal fascia. Debrided tissue specimens were sent for culture and pathological analysis.
The following day she continued to have high fevers with elevation of the white blood cell count. Tissue culture showed no organisms. Antibiotic coverage was broadened to include multiagent coverage.
Despite broad-spectrum antibiotics and multiple debridements, the abdominal wall necrosis continued to progress (Fig. 1). Additional diagnoses presenting with progressive skin necrosis were entertained, among them being PG. Steroid therapy for PG containment was considered alongside the option of complete resection of the abdominal wall. Ultimately, steroid therapy was initiated, and after 12 hours of IV glucocorticoid therapy, containment of erythema was noted. Surgical exploration revealed no progression of skin necrosis. Tissue biopsy results were compatible with the diagnosis of PG (Fig. 2).
The patient continued to respond favorably to steroids and improved over the following 3 weeks. Before discharge, she received skin grafting of the residual skin defects and was discharged on POD 34 (Fig. 3).
The case represents an unusual etiology of postoperative fever and wound breakdown. The presentation of PG mimics an infectious process and is often misdiagnosed.4,5 The suggested diagnostic criteria for PG are listed in Table 1.2 The prognosis of PG is generally favorable.6
In a case by Bisarya et al,4 PG on a patient’s right leg was initially diagnosed as necrotizing fasciitis. With failure of antibiotic therapy and surgical control, PG was suspected. Further, Bennett et al5 describe a patient with pustular lesions at the site of surgical release of tarsal tunnel syndrome misdiagnosed as cellulitis and abscess formation. A diagnosis of PG was suspected when pustular lesions developed at a separate skin graft donor site (ie, pathergy).
In our case, there was a similar emphasis on an infectious etiology. However, several findings should have led us away from this suspicion. On inspection of the wound, the pattern of tissue necrosis never extended beyond the dermis. The presence of satellite lesions at the Blake drain sites and continued local recurrence were suggestive of the pathergy phenomenon.7 Surgical debridement in suspected PG is contraindicated. Pathergy is observed in approximately 25–50% of patients with PG.8 We aggravated our patient’s lesions through repeated debridement.
Another major detractor from an infectious etiology was that powerful antimicrobial agents had no effect on retarding the progression of the lesions. Furthermore, repeated negative wound cultures should have prompted a reexamination of our diagnosis.
A review of literature demonstrated no uniform therapy for PG.1,2,7 The most commonly used protocol involves use of high-dose systemic corticosteroids; Prednisolone, 60 and 120 mg IV, is the initial treatment of choice.1,2,7 We administered hydrocortisone 100 mg IV every 6 hours, with good effect. Additionally, cyclosporine can be used as an adjunct to steroids or, alternatively, if steroids fail. A dose of 3–5 mg/kg/d is usually used for 3 weeks.1,2,7 However, 66% and 70% recurrence rates have been reported in patients treated with cyclosporine and prednisolone, respectively.6 PG has also been successfully treated with infliximab and combinations of corticosteroids and cytotoxic agents such as azathioprine.9,10
PG is a rare inflammatory skin condition. The view that an infectious etiology was responsible delayed the diagnosis of PG. In patients with irregular, progressive surgical site lesions, yielding no organism on culture, unresponsive to antibiotics and source control measures, alternatives to infectious agents should be considered. Rapid patient improvement, in concert with confirmatory histological findings, established the diagnosis of PG. As there is no accurate assay for diagnosis of PG currently, the future development of such tests can possibly alleviate diagnostic delays and inappropriate surgical intervention.
2. Powell FC, Hackett BC, Wallach DGoldsmith LA, Katz SI, Gilchrest BA, et al. Chapter 33: Pyoderma gangrenosum. In: Fitzpatrick’s Dermatology in General Medicine. 20128th ed New York: McGraw-Hill Available at: http://www.accessmedicine.com/content.aspx?aID=56031301
. Accessed May 26, 2013.
3. Su WP, Schroeter AL, Perry HO, et al. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol. 1986;13:323–330
4. Bisarya K, Azzopardi S, Lye G, et al. Necrotizing fasciitis versus pyoderma gangrenosum: securing the correct diagnosis! A case report and literature review. Eplasty. 2011;11:e24
5. Bennett CR, Brage ME, Mass DP. Pyoderma gangrenosum mimicking postoperative infection in the extremities. A report of two cases. J Bone Joint Surg Am. 1999;81:1013–1018
6. Uwe W. Pyoderma gangrenosum—a review. Orphanet J Rare Dis. 2007;2:19
7. Brooklyn T, Brooklyn T, Dunnill G, et al. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333:181–184
8. Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000;79:37–46
9. Ueda M, Katoh M, Tanizaki H, et al. Refractory pyoderma gangrenosum associated with ulcerative colitis successfully treated with infliximab. Dermatol Online J. 2012;18:12
© 2014 American Society of Plastic Surgeons
10. Rozin AP, Balbir-Gurman A, Gilead L, et al. Combined therapy for pyoderma gangrenosum. Ann Rheum Dis. 2004;63:888–889